On Thursday, Following U.S. Stocks were among the “Top Losers”: Warren Resources, (NASDAQ:WRES), Real Goods Solar, (NASDAQ:RGSE), Uranium Energy, (NYSEMKT:UEC), Second Sight Medical Products, (NASDAQ:EYES)
Warren Resources, Inc. (NASDAQ:WRES), with shares declined -13.28%, closed at $1.11.
Real Goods Solar, Inc. (NASDAQ:RGSE), with shares dropped -12.80%, settled at $0.293.
Uranium Energy Corp. (NYSEMKT:UEC), with shares dipped -12.66%, and closed at $1.38.
Second Sight Medical Products Inc (NASDAQ:EYES), plummeted -12.47%, and closed at $13.97.
Latest NEWS regarding these Stocks are depicted underneath:
Warren Resources Inc. (NASDAQ:WRES)
Warren Resources Inc. (WRES), stated its fourth quarter and full-year 2014 financial and operating results.
Full year 2014 Results:
- For the year ended December 31, 2014, Warren stated net revenue of $24.0 million, or $0.31 per diluted share, contrast to net revenue of $30.4 million for the year in 2013, or $0.42 per diluted share.
- Not including the influence of $7.5 million of unrealized non-cash gains on commodity derivatives resulting from mark-to-market accounting, $1.2 million of net severance expense, $4.2 million of attainment expenses, $1.1 million related to a non-cash credit to litigation expense and $2.2 million of other revenue, Warren’s full-year 2014 adjusted net revenue* was $18.6 million, or $0.24 per diluted share, which compares to adjusted net revenue of $28.6 million in 2013, or $0.39 per share.
- Warren’s full-year 2014 cash flow from operations was $84.0 million contrast to $79.4 million in 2013. The Corporation’s full-year 2014 discretionary cash flow* was $75.7 million, contrast to $80.0 million in 2013. EBITDA* in 2014 was $90.1 million, contrast to $78.2 million in 2013.
- Production volumes and financial results for the full year 2014 only reflect the influence of the Marcellus assets after the close of the attainment on August 11, 2014. Due to U.S. GAAP accounting rules Warren’s results exclude the influence of Marcellus operations from July 1, 2014 through August 10, 2014, the benefit from which is reflected as an adjustment to the purchase price of the assets on the Corporation’s balance sheet in oil and gas properties. As a result, Warren’s full year 2014 results exclude $7.8 million of revenue from operations from the Marcellus assets generated during the period from July 1st through August 10th, 2014. Results from the Marcellus operations in the first half of 2014, preceding to the attainment from Citrus Energy, are also excluded, except where pro forma results are indicated.
- For the year ended December 31, 2014, Warren produced about 22.8 net Bcfe, an average of 62.5 MMcfe/d, a 77% raise over the 12.9 net Bcfe produced in 2013. Oil production for the full year 2014 totaled about 1,118,000 net barrels of oil, an average of 3,064 BO/d, contrast to about 1,105,000 net barrels of oil for 2013. Warren’s natural gas production for the full year 2014 totaled about 16.1 net Bcf, an average of 44.1 MMcf/d, contrast to about 6.2 net Bcf for 2013.
- The production growth for the full year 2014 is primarily attributable to production from the Corporation’s Marcellus assets. However, due to U.S. GAAP accounting rules as noted above, production volumes for the full year 2014 exclude about 3.6 net Bcf of natural gas from the Marcellus related to operations from July 1st through August 10th, 2014. Furthermore, Warren’s stated production volumes in 2014 also exclude about 13.0 net Bcf of natural gas from the Marcellus operations in the first half of the year, preceding to the attainment from Citrus Energy.
- For the full year 2014, the average realized price per barrel of oil was $86.02, contrast to $97.12 for 2013. The realized price Mcf of natural gas averaged $3.06 for the full year 2014, contrast to $3.31 for 2013. These realized commodity prices exclude the effect of derivatives and hedging activities.
- For the full year 2014, oil and gas proceeds raised 14% to $145.4 million contrast to $127.9 million in 2013. The proceed raise was driven by the raise in production volumes, which more than offset the decrease in realized prices.
- Total operating expenses raised to $126.7 million in 2014, contrast to $97.3 million during 2013, primarily due to raised operating activity and higher production volumes. On a per unit basis operating expenses reduced year-over-year in 2014 from 2013, with LOE per Mcfe decreasing 26% to $2.12 and DD&A per Mcfe 29% lower to $2.48. The decrease in per unit operating expense reflects the influence of the low cost Marcellus assets and a decrease in the overall depletion rate.
- General and Administrative (“G&A”) expenses reduced by 1% to $15.3 million in 2014, contrast to $15.4 million in 2013. On a per unit basis G&A declined 44% in 2014 from 2013, to $0.67/Mcfe. Non-cash stock-based compensation expense, a non-cash component of G&A, was $1.6 million for the year ended 2014, contrast to $2.1 million for 2013.
- The Corporation had a net gain on derivative financial instruments of $7.4 million for the year ended December 31, 2014, which was comprised of $7.5 million of unrealized, non-cash gains on commodity derivatives and $0.1 million realized loss on commodity derivatives.
Warren Resources, Inc., an independent energy corporation, is engaged in the exploration, development, and production of onshore crude oil and gas reserves.
Real Goods Solar, Inc. (NASDAQ:RGSE)
Real Goods Solar, Inc. (RGSE), stock has price to sale value of 0.20, however, price to book value is 1.27. With recent decline, the year-to-date (YTD) performance reflected a -38.96% decline below last year. During the past month the stock lose -20.81%, bringing three-month performance to -46.73% and six-month performance to -80.97%. The mean recommendation of analysts for this stock is 3.00. (where 1=Buy, 5=Sale).
Real Goods Solar, Inc. operates as a residential and commercial solar energy engineering, procurement, and construction corporation in the United States. It provides commercial and residential solar energy solutions.
Uranium Energy Corp. (NYSEMKT:UEC)
Uranium Energy Corp. (UEC), reported in accordance with NYSE MKT requirements, the filing of the Corporation’s quarterly report on Form 10-Q for the six months ended January 31, 2015 with the U.S. Securities and Exchange Commission (the “SEC”). This Form 10-Q filing, which comprises the Corporation’s condensed merged financial statements, related notes thereto and administration’s discussion and analysis, is accessible for viewing on the SEC’s website at http://www.sec.gov/edgar.shtml or on the Corporation’s website at www.uraniumenergy.com.
Uranium Energy Corp. engages in the exploration, extraction, and processing of uranium concentrates on projects located in the United States and the Republic of Paraguay.
Second Sight Medical Products, Inc. (NASDAQ:EYES)
Second Sight Medical Products, Inc. (EYES), stated financial results for the three- and twelve- month periods ended December 31, 2014.
Full Year 2014 Financial Results:
Total proceed was $3.4 million in 2014, contrast to $1.6 million in 2013. The raise reflects volume growth in the number of implanted Argus II retinal prostheses. The Corporation implanted 29 Argus II retinal prostheses in 2014, contrast to 22 in 2013.
Gross loss in 2014 was $(0.2) million, contrast to a gross loss of $(4.1) million in 2013. The improvement is primarily due to higher proceeds from the aforementioned raise in implants, in addition to a lower cost of goods sold when contrast to 2013.
Total costs and operating expenses in 2014 were $21.1 million, contrast with $13.9 million in 2013. This raise is primarily due to raised investments in sales, marketing, and research and development, as well raised costs associated with Second Sight being publicly-traded, partially offset by lower clinical and regulatory costs in 2014 following FDA approval.
Operating loss in 2014 was $(21.2) million, contrast to an operating loss of $(18.0) million in 2013.
Net loss for the year ended December 31, 2014 was $(35.2) million, or $(1.41) per share, contrast with a net loss of $(23.0) million, or $(1.02) per share, in 2013. Non-GAAP adjusted net loss in 2014, not including non-cash expenses, was $(19.4) million, or $(0.77) per share contrast with Non-GAAP adjusted net loss of $(17.2) million in 2013, or $(0.76) per share.
Second Sight Medical Products, Inc., a medical device corporation, develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
